-
CDK Related Products (487)
Related Products (487)
-
Reziciclideg
0 ImagesCat. No.: HY-187921CAS No.: 3011828-23-9Reziciclideg is a cyclin-dependent kinase (CDK) degrader and antitumor agent. Reziciclideg is applicable for cancer research.
-
rel-(2S,3R)-Voruciclib
0 ImagesCat. No.: HY-12422CCAS No.: 1253731-24-6rel-(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active CDK inhibitor.
-
CDK7-IN-25
0 ImagesCat. No.: HY-156705CAS No.: 2009209-60-1CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) that can be used in cancer research.
-
CCNE1 degrader-1
0 ImagesCat. No.: HY-186127CAS No.: 3116573-90-8CCNE1 degrader-1 (I-2) is a degrader targeting CCNE1. CCNE1 degrader-1 can be used in cancer-related research.
-
CDK2-IN-19
0 ImagesCat. No.: HY-155966CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors.
-
CDK2-IN-11
0 ImagesCat. No.: HY-150572CAS No.: 2410402-82-1CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer.
-
CDK4/6-IN-5
0 ImagesCat. No.: HY-139449CAS No.: 2380321-50-4
-
Apoptosis inducer 49
0 ImagesCat. No.: HY-178940Apoptosis inducer 49 is a selective apoptosis inducer with high specificity against CCRF-CEM leukemia cells (IC50 = 2.68 μM). Apoptosis inducer 49 enhances RNA synthesis and replication stress, activates the Chk1-p21 axis, leading to S-phase arrest. Apoptosis inducer 49 can inhibit Bcl-2 and activate caspase-3. Apoptosis inducer 49 can be used for the study of Leukemia.
-
CDK2/CycD1 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70671CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK2.
-
AG-024104
0 ImagesCat. No.: HY-123238CAS No.: 750575-23-6AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development.
-
FAK1/2 ligand-1
0 ImagesCat. No.: HY-184307FAK1/2 Ligand-1 is a FAK1/FAK2 ligand with KD values of 2.9 μM and 2.5 μM for binding to FAK1 and FAK2, respectively. FAK1/2 Ligand-1 induces G2/M phase arrest, activates DNA damage-related signaling pathways, and reduces the phosphorylation level of CDK1. Antitumor agent-220 is applicable to the research of triple-negative breast cancer.
-
Cucurbitacin E (Standard)
0 ImagesCat. No.: HY-N0417RCAS No.: 18444-66-1Synonyms: α-Elaterin (Standard); α-Elaterine (Standard)Cucurbitacin E (Standard) is the analytical standard of Cucurbitacin E. This product is intended for research and analytical applications. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.
-
Tubulin-IN-66
0 ImagesCat. No.: HY-182753CAS No.: 3110538-32-1Tubulin-IN-66 is a tubulin (tubulin) and P-gp inhibitor with antiproliferative activity against cancer cells. Tubulin-IN-66 covalently binds to the Colchicine (HY-16569)-binding site at Cys239 of the β-tubulin subunit, inhibits tubulin polymerization and disrupts the microtubule network. Tubulin-IN-66 inhibits P-gp function to overcome multidrug resistance. Tubulin-IN-66 arrests the cell cycle at the G2/M phase and induces apoptosis (apoptosis). Tubulin-IN-66 inhibits colony formation and migration of cancer cells. Tubulin-IN-66 can be used in the research of tumors such as breast cancer.
![[pThr3]-CDK5 Substrate TFA](https://file.medchemexpress.com/product_pic/hy-p1906a.gif "Click to View [pThr3]-CDK5 Substrate TFA Product Detail")
-
CDK20/CycH Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70675CDK20 is a major controller of cell cycle checkpoints, which regulate cell growth and proliferation and perform a role in the development of many malignancies. CDK20 is thought to have Cyclin-dependent activating kinase (CAK) activity for CDK2 when it is complexed with Cyclin H. CDK20/CycH Recombinant Human Active Protein Kinase can be used to study the function of CDK20/CycH.
